Malarial Drug Delivery Systems Advances in Treatment of Infectious Diseases /
The disability-adjusted life year (DALY) is a generic measure of health effect that can be used in cost-effectiveness analysis as an alternative to the quality-adjusted life year (QALY). Infectious diseases are one of the major to cause of significant losses of DALY and QALY. Human infectious diseas...
Saved in:
| Corporate Author: | |
|---|---|
| Other Authors: | , |
| Format: | Electronic eBook |
| Language: | English |
| Published: |
Cham :
Springer International Publishing : Imprint: Springer,
2023.
|
| Edition: | 1st ed. 2023. |
| Subjects: | |
| Online Access: | https://doi.org/10.1007/978-3-031-15848-3 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
MARC
| LEADER | 00000nam a22000005i 4500 | ||
|---|---|---|---|
| 001 | 978-3-031-15848-3 | ||
| 003 | DE-He213 | ||
| 005 | 20260810114852.0 | ||
| 007 | cr nn 008mamaa | ||
| 008 | 230306s2023 sz | o |||| 0|eng d | ||
| 020 | |a 9783031158483 |9 978-3-031-15848-3 | ||
| 024 | 7 | |a 10.1007/978-3-031-15848-3 |2 doi | |
| 050 | 4 | |a RS199.5 | |
| 072 | 7 | |a TCB |2 bicssc | |
| 072 | 7 | |a SCI010000 |2 bisacsh | |
| 072 | 7 | |a TCB |2 thema | |
| 082 | 0 | 4 | |a 615.6 |2 23 |
| 245 | 1 | 0 | |a Malarial Drug Delivery Systems |h [electronic resource] : |b Advances in Treatment of Infectious Diseases / |c edited by Ranjita Shegokar, Yashwant Pathak. |
| 250 | |a 1st ed. 2023. | ||
| 264 | 1 | |a Cham : |b Springer International Publishing : |b Imprint: Springer, |c 2023. | |
| 300 | |a 1 online resource (X, 395 p. 55 illus.). |b 49 illus. in color. | ||
| 336 | |a text |b txt |2 rdacontent | ||
| 337 | |a computer |b c |2 rdamedia | ||
| 338 | |a online resource |b cr |2 rdacarrier | ||
| 341 | 0 | |b Table of contents navigation |2 onix | |
| 341 | 0 | |b Single logical reading order |2 onix | |
| 341 | 0 | |b Short alternative textual descriptions |2 onix | |
| 341 | 0 | |b Use of color is not sole means of conveying information |2 onix | |
| 341 | 0 | |b Use of high contrast between text and background color |2 onix | |
| 341 | 0 | |b Next / Previous structural navigation |2 onix | |
| 341 | 0 | |b All non-decorative content supports reading without sight |2 onix | |
| 347 | |a text file |b PDF |2 rda | ||
| 505 | 0 | |a Malaria: Cellular Understanding of Disease -- Drug Resistance, Statistics and Patent Status -- Malaria: Current Treatment Options -- Polymeric Nanoparticles in Malaria -- Solid Lipid Nanoparticles in Malaria -- Dendrimers in Malaria -- Liposomes in Malaria -- Micro and Nano Emulsions in Malaria -- Nanosuspension in Malaria -- Alginate and Gelatin Nanoparticles in Malaria -- Niosomes in Malaria -- Metal Nanoparticles in Malaria -- Nanotechnology in Malaria Diagnosis -- Nanotechnology-based Vaccination -- Herbal Platforms in Malaria -- Surface-modified Drug Delivery Systems in Malaria,- Clinical Trials in Malaria -- Malaria-Overall Picture -- New Drugs in Synthesis Research for Malaria -- Disease Models In Malaria Research. | |
| 520 | |a The disability-adjusted life year (DALY) is a generic measure of health effect that can be used in cost-effectiveness analysis as an alternative to the quality-adjusted life year (QALY). Infectious diseases are one of the major to cause of significant losses of DALY and QALY. Human infectious diseases are disorders that are triggered by the micro-organisms such as bacteria, fungi, viruses, or parasites. The majority of such diseases are contagious and create a public health menace. There are several reasons why infectious diseases are deadly diseases, and one of the primary reasons is the drug resistance developed over time. Drug resistance-associated mutations are linked to increasing drug efflux, modifications of the drugs, or their targets. Every year, new drugs are being approved by FDA to treat infectious diseases. Nonetheless, infectious diseases will undoubtedly persist as permanent and main threats to humanity for now and in the future, primarily due to increased longevity thatalmost always comes at the cost of impaired immunity. A total of four books are covered under the series of Infectious drug diseases. - Malarial drug delivery systems - Tubercular drug delivery systems - Viral drug delivery systems - Infectious disease drug delivery systems The theme of the first book is Malaria. This book compiles the complete road map of malarial drug delivery systems by understanding the pathophysiology of the disease, the current state of malaria across the globe, new clinical trials, emerging drugs, and the development of novel drug delivery platforms. Various novel micro-and nano-formulations using promising technologies are being explored to deliver the malarial drug via different administration routes. This book addresses the gap between new approaches and old treatment modalities and how the former is superior in pharmacological performance when tested in in-vitro and in-vivo. Audiences from a broad range of groups, from researchers, academicians, and public health bodies to regulatory experts, can benefit from the compiled information to learn more about patient needs and current research advances in the field of malarial research. | ||
| 532 | 8 | |a Accessibility summary: This PDF does not fully comply with PDF/UA standards, but does feature limited screen reader support, described non-text content (images, graphs), bookmarks for easy navigation and searchable, selectable text. Users of assistive technologies may experience difficulty navigating or interpreting content in this document. We recognize the importance of accessibility, and we welcome queries about accessibility for any of our products. If you have a question or an access need, please get in touch with us at accessibilitysupport@springernature.com. | |
| 532 | 8 | |a No reading system accessibility options actively disabled | |
| 532 | 8 | |a Publisher contact for further accessibility information: accessibilitysupport@springernature.com | |
| 588 | |a Print version record. | ||
| 650 | 0 | |a Drug delivery systems. | |
| 650 | 0 | |a Nanobiotechnology. | |
| 650 | 0 | |a Pharmaceutical chemistry. | |
| 650 | 0 | |a Tropical medicine. | |
| 650 | 0 | |a Pharmacology. | |
| 650 | 0 | |a Medical microbiology. | |
| 650 | 1 | 4 | |a Drug Delivery. |
| 650 | 2 | 4 | |a Nanobiotechnology. |
| 650 | 2 | 4 | |a Pharmaceutics. |
| 650 | 2 | 4 | |a Tropical Medicine. |
| 650 | 2 | 4 | |a Pharmacology. |
| 650 | 2 | 4 | |a Medical Microbiology. |
| 700 | 1 | |a Shegokar, Ranjita. |e editor. |0 (orcid)0009-0009-2643-8944 |1 https://orcid.org/0009-0009-2643-8944 |4 edt |4 http://id.loc.gov/vocabulary/relators/edt | |
| 700 | 1 | |a Pathak, Yashwant. |e editor. |4 edt |4 http://id.loc.gov/vocabulary/relators/edt | |
| 710 | 2 | |a SpringerLink (Online service) | |
| 773 | 0 | |t Springer Nature eBook | |
| 776 | 0 | 8 | |i Printed edition: |z 9783031158476 |
| 776 | 0 | 8 | |i Printed edition: |z 9783031158490 |
| 776 | 0 | 8 | |i Printed edition: |z 9783031165061 |
| 856 | 4 | 0 | |u https://doi.org/10.1007/978-3-031-15848-3 |
| 912 | |a ZDB-2-SBL | ||
| 912 | |a ZDB-2-SXB | ||
| 950 | |a Biomedical and Life Sciences (SpringerNature-11642) | ||
| 950 | |a Biomedical and Life Sciences (R0) (SpringerNature-43708) | ||